[{"orgOrder":0,"company":"Center for International Blood and Marrow Transplant Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase IV","graph3":"Center for International Blood and Marrow Transplant Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Center for International Blood and Marrow Transplant Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Center for International Blood and Marrow Transplant Research \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Salix Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing reverse thermal gel indicated for primary chemoablative treatment of LG-UTUC in adults.

                          Brand Name : Jelmyto

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 04, 2024

                          Lead Product(s) : Mitomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Relistor (methylnaltrexone bromide) is an opioid antagonist, its subcutaneous formulation is being investigated in patients with resectable head and neck squamous cell carcinoma.

                          Brand Name : Relistor

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 06, 2024

                          Lead Product(s) : Naltrexone Methobromide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy delivering a human IFNα2b gene to the bladder for treating BCG-unresponsive non-muscle invasive bladder cancer.

                          Brand Name : Adstiladrin

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          January 24, 2024

                          Lead Product(s) : Nadofaragene Firadenovec-vncg

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Lutathera (lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) is an Advanced Accelerator Applications RLT approved in the United States for the treatment of SSTR-positive GEP-NETs.

                          Brand Name : Lutathera

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 25, 2023

                          Lead Product(s) : Dotatate Lutenium Lu-177

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Legend Biotech entered into the agreement with Janssen to develop, manufacture and commercialize cilta-cel for the treatment of multiple myeloma. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy.

                          Brand Name : Cilta-cel

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : $350.0 million

                          February 11, 2022

                          Lead Product(s) : Ciltacabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : $650.0 million

                          Deal Type : Collaboration

                          blank

                          06

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : NUBEQA significantly reduced the risk of death by 31%, offering men with non-metastatic castration-resistant prostate cancer (nmCRPC) extended survival for a greater chance of living longer.

                          Brand Name : Nubeqa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 08, 2021

                          Lead Product(s) : Darolutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The trial demonstrated encouraging response rates and duration of response with Opdivo in SCLC, an aggressive and difficult-to-treat cancer.

                          Brand Name : Opdivo

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 29, 2020

                          Lead Product(s) : Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Center for International Blood and Marrow Transplant Research

                          Country arrow
                          Cosmoprof India
                          Not Confirmed

                          Center for International Blood and Marrow Transplant Research

                          Country arrow
                          Cosmoprof India
                          Not Confirmed

                          Details : Yescarta is the first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

                          Brand Name : Yescarta

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 08, 2020

                          Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Cosmoprof India
                          Not Confirmed